Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use
News Release (News), NCT05047601 (history)
, Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use, News Release (News), NCT05047601
PEP RCT showing lower risk of cases with treatment, without statistical significance. The group sizes and event counts have not been provided.
|
risk of case, 37.0% lower, RR 0.63, p = 0.05, treatment 986, control 985, 10 day treatment, group sizes estimated, p-value unknown, >0.05.
|
|
risk of case, 32.0% lower, RR 0.68, p = 0.05, treatment 986, control 985, 5 day treatment, group sizes estimated, p-value unknown, >0.05.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pfizer et al., 29 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT05047601 (history).
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.